Nebenwirkungen · Nemluvio
Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 7
HOS-151706 · Präparat HOS-100595
The majority of WOA events occurred within the first two months of treatment initiation and all were reported as mild or moderate in severity. Most patients experienced a single event of WOA during treatment and the event resolved with standard of care asthma medications (inhalers) without the use of systemic steroids. None led to permanent discontinuation of treatment. The incidence of WOA did not increase with longer term exposure to nemolizumab (up to Week 52) in the PN open-label long- term extension study.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T09:55:00Z · SHA-256 1bb265a9f40d2d9ad19bebf360d00ee88a562f44d6c6e4cae75604ad99ebd76a · Passage a601212e099c9dda75c8e0b0788b0a1cdaa8ce4fea13dc97551fd02470ce7c07 · Zeichen 4532–5048 im Abschnitt